Form 4: Jazz Pharmaceuticals Director Sells Shares

Jazz Pharmaceuticals Director Bruce C. Cozadd reported a sale of 6,000 ordinary shares for $235.12 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Director Bruce C. Cozadd of Jazz Pharmaceuticals plc (JAZZ) has reported a transaction involving the sale of 6,000 ordinary shares.
• The sale occurred on June 1, 2026, at a price of $235.12 per share.
• This transaction was conducted under a Rule 10b5-1 trading plan adopted on November 26, 2025.
• Following the transaction, Mr. Cozadd beneficially owns 372,682 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the sale was executed under a pre-established 10b5-1 plan, indicating it was not a discretionary decision based on current market conditions.

Negatives

• Director sale of a significant number of shares, although executed under a pre-planned trading strategy.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it solely reports a past transaction.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, can sometimes be interpreted by the market as a signal of reduced confidence, though the pre-planned nature of this transaction mitigates direct interpretation of current sentiment.

Stakeholder Impact

• Shareholders may note the sale by a director, but the pre-planned nature of the transaction under a 10b5-1 plan suggests it is not indicative of a change in the director's overall confidence in the company.

Key Dates

Keywords

Jazz Pharmaceuticals, JAZZ, Form 4, Insider Trading, Share Sale, 10b5-1 Plan, Bruce C. Cozadd, Director Transaction